Host-targeted antiviral to achieve a functional cure for chronic hepatitis B
Official title: Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure
Funded at Evrys Bio, INC. · NIH-11364197 · Data updated 2026-11-12
A research project tests a new drug strategy that aims to clear signs of hepatitis B in people who have a chronic infection.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evrys Bio, INC. NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project start | August 20, 2021 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $961,797 |
| NIH project number | 5R44AI157725-04 |
| Project ID | NIH-11364197 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with chronic hepatitis B infection who have not yet achieved a functional cure and are eligible for early-phase therapeutic studies.
✕Less likely to help
Patients with acute HBV infection or those not eligible for early-phase antiviral trials may not benefit.
What this research studies
This project focuses on a host-targeted approach using SIRT2 inhibitors to reduce hepatitis B markers in liver cells and blood. It will first show the therapy can lower cccDNA and other viral indicators in infected liver cells, including different HBV genotypes. If successful, the work could move toward early clinical studies to see if people with chronic HBV might reach a functional cure where the virus becomes undetectable. The research is conducted by Evrys Bio and aims to rapidly translate lab findings into potential patient benefits.
Why it matters
Potential benefit: If successful, the approach could contribute to a functional cure for chronic hepatitis B, reducing the need for long-term antiviral therapy.
How similar studies have gone: Prior work shows host-targeted antivirals can reduce viral markers in cells, but translating to a cure in people remains an experimental area.
Where this research is happening
-
Evrys Bio, INC.
Doylestown, United States Active
Researchers
- Principal investigator: Remiszewski, Stacy — Evrys Bio, INC.
- Study coordinator: Remiszewski, Stacy
Related research
Other NIH-funded projects on the same topics.
-
HBV immune responses in functional cure and therapies guided by CD4 T cells and B cells
This grant studies how HBV-specific CD4 T cells and B cells behave in people with hepatitis B to identify clues for achieving a functional cure.
-
Therapeutic nucleic acid vaccine for chronic hepatitis B in people with HIV/HBV co-infection
A new genetic vaccine approach is being tested to help people living with both HIV and chronic hepatitis B reduce and potentially cure their HBV infection.
-
HBV immune responses and pathways linked to functional cure
Researchers will study how HBV-specific CD4 T cells and B cells behave in people with chronic hepatitis B to find what immune changes are needed for a functional cure.
-
Nanobodies to help clear HBV surface antigen and restore immunity
A small, targeted antibody therapy using nanobodies is being explored to lower hepatitis B surface antigen in people with chronic HBV, with the goal of helping the immune system clear the infection.
-
How immune cells help control chronic hepatitis B
This research looks at how two immune cell types (CD4 T cells and B cells) in adults with hepatitis B act differently in people who clear the virus versus those with long-term infection to find clues for treatments that could lead to a functional cure.
-
Long-acting injectable hepatitis B antivirals with an immune booster
This project is developing long-lasting injectable hepatitis B medicines combined with an immune stimulant for people living with chronic hepatitis B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.